As Amgen’s flagship PCSK9 cholesterol drug Repatha enjoys a bit of a renaissance on the back of impressive cardiovascular ...
In closing out the TDF/TAF litigation chapter, Gilead is simultaneously moving to a new era of HIV treatment altogether with ...
Long viewed as one of the biggest hype-to-disappointment stories in pharmaceutical history, the PCSK9 cholesterol drug class ...
After a yearslong struggle, Jazz Pharmaceuticals has called time on Zepzelca as a second-line treatment for small cell lung cancer. | After a yearslong struggle, Jazz Pharmaceuticals has called time ...
Nominations are now open for the 2026 Fiercest Women in Life Sciences. | Who should be a 2026 Fiercest Woman in Life Sciences ...
Growth of new drugs and a steady base business helped Bayer weather expected declines across Xarelto and Eylea sales in Q2, ...
Pfizer will reduce its costs by $2.5 billion in another round of cutbacks which will kick in next year and run through 2029. The New York company unveiled the plan in its second-quarter earnings ...
Johnson & Johnson has named Tom Cavanaugh as the next leader of its innovative medicines business, beginning Sept. 1, 2026.
In a milestone for IgA nephropathy, Otsuka’s Voyxact has shown for the first time in a phase 3 trial that a drug can stabilize patients’ kidney function decline to the normal rate seen in healthy ...
It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie acquired ...
Hackers recently accessed Amgen’s cloud environment, stealing sensitive patient health information and proprietary company ...
Two growing companies, Supernus Pharmaceuticals and Indivior Pharmaceuticals, have agreed to merge in an all-stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results